For the best user experience please use a browser to proceed.

THOR - Synthorx, Inc. price and analysis

Fundamentals:
Basic Info:
  • Market Cap:
  • Exchange:
  • Shares Float:
  • Shares Outstanding:
  • Revenue Per Employee:
Advanced Info:
  • ROE ttm:
  • ROA ttm:
  • Beta:
  • EPS:
  • Debt Ratio ttm:
  • Debt / Equity Ratio ttm:
  • Payout Ratio ttm:
Cash Ratios:
  • Cash Ratio ttm:
  • Current Ratio ttm:
  • Quick Ratio ttm:
Key Ratios:
  • P/E trailing 12 month:
  • P/E forward:
  • P/E trailing 12m high:
  • P/E trailing 12m low:
  • P/S trailing 12 month:
  • EV/S trailing 12 month:
  • P/B trailing 12 month:
  • PEG ratio:
Shorts:
  • Shares Short:
  • Shares Short Prev Month:
  • Days to Cover:
  • Short Percent Float:
  • Short Percent Outstanding:
Ownership:
  • Percent Insiders:
  • Percent Institutions:
Margins:
  • Gross Profit Margin ttm:
  • EBITDA Margin ttm:
  • Operating Margin ttm:
  • Net Income Margin ttm:
Target Prices:
  • Target Price High:
  • Target Price Low:
  • Target Price Mean:
  • Number of Analysts:
Key Prices:
  • 52 Week High:
  • 52 Week Low:
  • 50 Day Moving Average:
  • 200 Day Moving Average:
Dividends:
  • Trailing Dividend yld:
  • Forward Dividend yld:
  • Payout Ratio:
  • Ex-Dividend date:
Current Quarter Estimates:
  • Current Quarter EPS estimate:
  • Current Quarter revenue estimate:
Latest News:
French and Benelux stocks-Factors to watch on Dec 9Reuters2019-12-10 00:12:00 EDT
Synthorx To Be Acquired By Sanofi For $2.5BYAHOO!2019-12-09 16:12:00 EDT
Why Synthorx Stock Is Soaring TodayThe Motley Fool2019-12-09 15:19:00 EDT
BLUE, PCG among premarket gainersSeeking Alpha2019-12-09 14:27:00 EDT
Sanofi to buy Synthorx for $2.5BSeeking Alpha2019-12-09 12:51:00 EDT
Sanofi to Buy U.S. Biotech Firm for $2.5 Billion in Cancer PushBloomberg on MSN.com2019-12-09 12:06:40 EDT
Click to expand the area.
Income Statements:
THOR - Synthorx, Inc. Income Statement
Unit: (million)
Qtr Revenue
Rev Growth yoy
Cost of Revenue
Gross Profit
Gross Profit Mgn
Research and Development
Selling, General & Administrative Expense
Operating Income
Operating Mgn
Net Income
Net Income Mgn
Generated by @earningsfly with ❤️
Cashflow Statements:
Not available at this time...
Balance Sheets:
THOR - Synthorx, Inc. Balance Sheet
Unit: (million)
Total Assets
Intangible Assets
Goodwill
Current Assets
Current Cash
Account Receivables
Inventory
Total Liabilities
Account Payables
Short Term Debt
Long Term Debt
Current Ratio
Debt Ratio
Debt/Equity Ratio
Generated by @earningsfly with ❤️
Latest Posts:
Not available at this time..
Synthorx, Inc.
Synthorx, Inc.

Synthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indicatio...
Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 38
Next Earnings Date: 2020-03-11
Keywords: Synthorx
Summary and stock analysis:
    606 Followers
    294.8m Followers
    Avg: 
     1 review, 13 jobs
    Basic Info:
    • Market Cap:
    • Exchange:
    • Shares Float:
    • Shares Outstanding:
    • Revenue Per Employee:
    Advanced Info:
    • ROE ttm:
    • ROA ttm:
    • Beta:
    • EPS:
    • Debt Ratio ttm:
    • Debt / Equity Ratio ttm:
    • Payout Ratio ttm:
    Cash Ratios:
    • Cash Ratio ttm:
    • Current Ratio ttm:
    • Quick Ratio ttm:
    Key Ratios:
    • P/E trailing 12 month:
    • P/E forward:
    • P/E trailing 12m high:
    • P/E trailing 12m low:
    • P/S trailing 12 month:
    • EV/S trailing 12 month:
    • P/B trailing 12 month:
    • PEG ratio:
    Shorts:
    • Shares Short:
    • Shares Short Prev Month:
    • Days to Cover:
    • Short Percent Float:
    • Short Percent Outstanding:
    Ownership:
    • Percent Insiders:
    • Percent Institutions:
    Margins:
    • Gross Profit Margin ttm:
    • EBITDA Margin ttm:
    • Operating Margin ttm:
    • Net Income Margin ttm:
    Target Prices:
    • Target Price High:
    • Target Price Low:
    • Target Price Mean:
    • Number of Analysts:
    Key Prices:
    • 52 Week High:
    • 52 Week Low:
    • 50 Day Moving Average:
    • 200 Day Moving Average:
    Dividends:
    • Trailing Dividend yld:
    • Forward Dividend yld:
    • Payout Ratio:
    • Ex-Dividend date:
    Current Quarter Estimates:
    • Current Quarter EPS estimate:
    • Current Quarter revenue estimate:
    Click to expand the area.
    Analyst Consensus:
    THOR - Synthorx, Inc. Analyst Opinions

    Generated by @earningsfly with ❤️
    Analyst Trends:
    THOR - Synthorx, Inc. Analyst Trends
    Generated by @earningsfly with ❤️
    Website Ranking Analysis:
    Google Trends Analysis:
    THOR - Synthorx, Inc. Google 5-year Trends Analysis
    Generated by @earningsfly with ❤️
    Employees Analysis:
    THOR - Synthorx, Inc. Employees Analysis
    Generated by @earningsfly with ❤️
    Institution & Insiders Analysis:
    THOR - Synthorx, Inc. Ownership Analysis
    Generated by @earningsfly with ❤️
    Debt & Cash Analysis:
    THOR - Synthorx, Inc. Cash and Debt Analysis(unit: USD)
    Generated by @earningsfly with ❤️
    Short Analysis:
    THOR - Synthorx, Inc. Shorts Analysis
    Generated by @earningsfly with 🚀
    Margins and Revenue:
    THOR - Synthorx, Inc. Revenue and Margins
    Generated by @earningsfly with 🚀
    Income Statement Analysis:
    THOR - Synthorx, Inc. Income Statement
    Unit: (million)
    Qtr Revenue
    Rev Growth yoy
    Cost of Revenue
    Gross Profit
    Gross Profit Mgn
    Research and Development
    Selling, General & Administrative Expense
    Operating Income
    Operating Mgn
    Net Income
    Net Income Mgn
    Generated by @earningsfly with ❤️
    Earnings Estimate Analysis:
    Not available at this time...
    Cashflow Analysis:
    Not available at this time...